[go: up one dir, main page]

HUP9904121A2 - Orális, késleltetett, azonnali hatóanyag-leadású készítmény és eljárás a készítmény előállítására - Google Patents

Orális, késleltetett, azonnali hatóanyag-leadású készítmény és eljárás a készítmény előállítására

Info

Publication number
HUP9904121A2
HUP9904121A2 HU9904121A HUP9904121A HUP9904121A2 HU P9904121 A2 HUP9904121 A2 HU P9904121A2 HU 9904121 A HU9904121 A HU 9904121A HU P9904121 A HUP9904121 A HU P9904121A HU P9904121 A2 HUP9904121 A2 HU P9904121A2
Authority
HU
Hungary
Prior art keywords
immediate
preparation
delayed
release
immediate release
Prior art date
Application number
HU9904121A
Other languages
English (en)
Inventor
Jules Alex Cornelis Elbers
Henderik Willem Frijlink
Wienman Emerald Philips
Paulus Maria Van Balken
Original Assignee
Duphar International Research B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar International Research B.V. filed Critical Duphar International Research B.V.
Publication of HUP9904121A2 publication Critical patent/HUP9904121A2/hu
Publication of HUP9904121A3 publication Critical patent/HUP9904121A3/hu
Publication of HU226693B1 publication Critical patent/HU226693B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)

Abstract

A találmány őrális késleltetett azőnnali hatóanyag-leadásúkészítményre, az ilyen készítmény előállítására alkalmas eljárására ésegy késleltetett azőnnali hatóanyag-leadású készítmény és egy azőnnalihatóanyag-leadású készítmény kőmbinációjára vőnatkőzik. Az őráliskésleltetett azőnnali hatóanyag-leadású készítmény egy vagy többhatóanyagőt tartalmazó préselt magból áll, amelyet bevőnat vesz körül,ahől a hatóanyag a magból azáltal szabadűl fel, hőgy a bevőnat egymeghatárőzőtt késési (lag) idő űtán felreped, a mag egy vagy többközvetlen hatóanyag-leadású hőrdőzót tartalmaz és a győmőr-bél nedvekhatásának kitéve lényegesen nem dűzzad. A találmány szerintikésleltetett azőnnali hatóanyag-leadású készítménybe a hatóanyagőkszéles köre belefőglalható. ŕ
HU9904121A 1996-09-23 1997-09-18 Oral delayed immediate release formulation and method of preparation therefore HU226693B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202651 1996-09-23
PCT/EP1997/005234 WO1998013029A1 (en) 1996-09-23 1997-09-18 Oral delayed immediate release formulation and method of preparation therefor

Publications (3)

Publication Number Publication Date
HUP9904121A2 true HUP9904121A2 (hu) 2000-04-28
HUP9904121A3 HUP9904121A3 (en) 2004-10-28
HU226693B1 HU226693B1 (en) 2009-06-29

Family

ID=8224414

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904121A HU226693B1 (en) 1996-09-23 1997-09-18 Oral delayed immediate release formulation and method of preparation therefore

Country Status (30)

Country Link
US (1) US6183780B1 (hu)
EP (1) EP0939623B1 (hu)
JP (1) JP4947824B2 (hu)
KR (1) KR100501966B1 (hu)
CN (1) CN1161110C (hu)
AT (1) ATE213627T1 (hu)
AU (1) AU717711B2 (hu)
BR (1) BR9711303A (hu)
CA (1) CA2263921C (hu)
CZ (1) CZ294641B6 (hu)
DE (1) DE69710756T2 (hu)
DK (1) DK0939623T3 (hu)
DZ (1) DZ2314A1 (hu)
ES (1) ES2172003T3 (hu)
HK (1) HK1019852A1 (hu)
HR (1) HRP970493A2 (hu)
HU (1) HU226693B1 (hu)
ID (1) ID22039A (hu)
IL (1) IL128565A (hu)
JO (1) JO2066B1 (hu)
NO (1) NO325763B1 (hu)
NZ (1) NZ334463A (hu)
PL (1) PL189016B1 (hu)
PT (1) PT939623E (hu)
RU (1) RU2193395C2 (hu)
SK (1) SK284263B6 (hu)
TR (1) TR199900641T2 (hu)
UA (1) UA72182C2 (hu)
WO (1) WO1998013029A1 (hu)
ZA (1) ZA978431B (hu)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
IL139541A0 (en) 1998-05-20 2004-02-08 Liposome Co Inc Novel particulate formulations
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
KR100812832B1 (ko) * 1998-11-02 2008-03-11 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
IE990406A1 (en) * 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1074249A1 (en) * 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
JP5209160B2 (ja) 1999-08-24 2013-06-12 エービーアイシー・バイオロジカル・ラボラトリーズ・リミテッド ワクチン組成物およびその使用方法
JP2003507413A (ja) * 1999-08-26 2003-02-25 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 徐放性鎮静催眠組成物およびそれに関連する方法
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
DE10012555A1 (de) * 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE512659T1 (de) 2003-04-24 2011-07-15 Jagotec Ag Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
DK1615626T3 (da) * 2003-04-24 2010-02-08 Jagotec Ag Tablet med farvet kerne
BRPI0318456B8 (pt) * 2003-08-08 2021-05-25 Biovail Laboratories Int Srl tablete com liberação modificada
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
KR20080007586A (ko) * 2005-04-12 2008-01-22 엘란 파마 인터내셔널 리미티드 세균감염증의 치료를 위한 세팔로스포린 함유 조절 방출조성물
PL2444079T3 (pl) 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
JP2009502908A (ja) 2005-07-29 2009-01-29 スティッチング グロニンゲン セントル フォー ドラッグ リサーチ ｐＨ制御パルス送達システム、その調製法及び使用法
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
EP1945189A4 (en) * 2005-11-03 2012-08-15 Sun Pharmaceutical Ind Ltd COATED TABLETS WITH EXTENDED MAGNETIC RETENTION
ES2400446T5 (es) * 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009021127A2 (en) * 2007-08-07 2009-02-12 Neurogen Corporation Controlled released compositions
JP5808037B2 (ja) 2007-10-19 2015-11-10 サーコード バイオサイエンス インク． 糖尿病性網膜症の治療のための組成物及び方法
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2749646A1 (en) * 2009-01-26 2010-07-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2314296A1 (en) * 2009-10-22 2011-04-27 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Orally Disintegrating Tablets of Betahistine
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012071220A1 (en) * 2010-11-23 2012-05-31 Transcept Pharmaceuticals, Inc. Compositions and methods for once-daily administration of a trilayer osmotic tablet
RU2453308C1 (ru) * 2010-12-20 2012-06-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Драже с оксиметилурацилом и мебеверина гидрохлоридом для лечения функциональных заболеваний желудочно-кишечного тракта
KR102258769B1 (ko) * 2011-10-14 2021-06-01 지엘팜텍주식회사 장용소화효소제 및 그 제조방법
DE102012105528A1 (de) 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
CN110922393A (zh) 2012-07-25 2020-03-27 诺华股份有限公司 Lfa-1抑制剂及其多晶型物
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6661531B2 (ja) 2013-10-10 2020-03-11 シナジー ファーマシューティカルズ インコーポレイテッド オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト
KR102207539B1 (ko) * 2015-06-30 2021-01-26 네우라드 리미티드 신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
CN108836948B (zh) * 2018-06-11 2024-04-12 宁波西敦医药包衣科技有限公司 一种利用包衣技术实现营养素可控制释放的产品
RU2695135C1 (ru) * 2018-07-11 2019-07-22 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения
CN110403912A (zh) * 2019-09-04 2019-11-05 西安科力康医药科技有限公司 缓控释包衣粉

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH666405A5 (de) * 1985-06-24 1988-07-29 Ciba Geigy Ag Feste, haltbare darreichungsformen mit elastischem filmueberzug.
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
GB9104854D0 (en) * 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
WO1993019741A1 (en) * 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6068859A (en) * 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin

Also Published As

Publication number Publication date
AU717711B2 (en) 2000-03-30
CZ294641B6 (cs) 2005-02-16
KR20010029536A (ko) 2001-04-06
NO991385L (no) 1999-05-25
US6183780B1 (en) 2001-02-06
NZ334463A (en) 2000-12-22
SK37699A3 (en) 1999-08-06
WO1998013029A1 (en) 1998-04-02
IL128565A (en) 2003-02-12
SK284263B6 (sk) 2004-12-01
EP0939623A1 (en) 1999-09-08
EP0939623B1 (en) 2002-02-27
IL128565A0 (en) 2000-01-31
ATE213627T1 (de) 2002-03-15
JP2001500885A (ja) 2001-01-23
JO2066B1 (en) 2000-05-21
NO991385D0 (no) 1999-03-22
HU226693B1 (en) 2009-06-29
DE69710756T2 (de) 2002-10-24
NO325763B1 (no) 2008-07-14
JP4947824B2 (ja) 2012-06-06
HRP970493A2 (en) 1998-08-31
DK0939623T3 (da) 2002-06-10
CN1231601A (zh) 1999-10-13
HUP9904121A3 (en) 2004-10-28
CA2263921C (en) 2006-05-23
ES2172003T3 (es) 2002-09-16
HK1019852A1 (en) 2000-03-03
AU4557097A (en) 1998-04-17
TR199900641T2 (xx) 1999-07-21
CZ99599A3 (cs) 1999-06-16
ZA978431B (en) 1998-03-26
CN1161110C (zh) 2004-08-11
CA2263921A1 (en) 1998-04-02
PL189016B1 (pl) 2005-06-30
DE69710756D1 (de) 2002-04-04
PL332245A1 (en) 1999-08-30
BR9711303A (pt) 1999-08-17
DZ2314A1 (fr) 2002-12-28
PT939623E (pt) 2002-08-30
UA72182C2 (en) 2005-02-15
ID22039A (id) 1999-08-26
KR100501966B1 (ko) 2005-07-20
RU2193395C2 (ru) 2002-11-27

Similar Documents

Publication Publication Date Title
HUP9904121A2 (hu) Orális, késleltetett, azonnali hatóanyag-leadású készítmény és eljárás a készítmény előállítására
CA2315927A1 (en) Oral pharmaceutical pulsed release dosage form
CA2232450A1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
AU6517596A (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
PL304060A1 (en) Solid dosed form of prolonged release for oral administration and method of obtaining same,
CA2369715A1 (en) Fast-dispersing dosage forms containing fish gelatin
CA2348871A1 (en) Multiparticulate modified release composition
HUP0000976A2 (hu) Protonpumpa inhibitort tartalmazó, több egységből pezsgőtablettává préselt gyógyszeradagolási formák
NZ314442A (en) Extended release formulation comprising venlafaxine hydrochloride, film coating composition
HU0500666D0 (en) Oral dosage preparation to release ingredients in oral cavity
EP0776660A3 (en) Long-lasting release nifedipine preparation
ES2046083A1 (es) Procedimiento para preparar composiciones de liberacion prolongada.
AP1748A (en) Chronotherapeutic dosage forms.
CA2290017A1 (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
UA63993C2 (uk) Фармацевтична лікарська форма, що швидко тане в роті (варіанти) та спосіб формування гранул
IS4976A (is) 7a-(z-Amínóakýl)estratríen, aðferð til að búa þautil, lyfjasamsetningar sem innihalda fyrrnefnd 7a-(z-amínóakýl)estratríen og notkun þeirra í framleiðslu læknislyfja
AU6136199A (en) Dosage form comprising therapeutic formulation
DE59507193D1 (de) VERFAHREN ZU hERSTELLUNG EINER MANTELTABLETTE MIT SPITZEM KERN
BG102228A (en) Medicamentous form with controlled release of slightly soluble medicamentous substances
IL109186A (en) Stable ingestable and absorbable nadh and nadph therapeutic compositions
WO2004028504A8 (en) Modified release dosage forms
WO1999022724A3 (en) Extended release formulation containing venlafaxin
EP0061217A3 (en) Ibuprofen-containing sustained release pharmaceutical composition
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
O'Keefe et al. Color and shade matching: the weak link in esthetic dentistry

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ABBOTT PRODUCTS OPERATIONS AG, CH

Free format text: FORMER OWNER(S): DUPHAR INTERNATIONAL RESEARCH B.V., NL

MM4A Lapse of definitive patent protection due to non-payment of fees